Cirle Alcantara Warren
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Cirle Alcantara Warren has a total of 178 co-authors. Here are the top co-authors by number of shared publications:
Jae Hyun Shin
Division of Infectious Diseases and International Health, University of Virginia, Charlottesville, USA
10 shared publications- Deiziane Viana da Silva Costa
Division of Infectious Diseases and International Health, University of Virginia, Charlottesville, USA
8 shared publications - Richard Littleton Guerrant
University of Virginia
8 shared publications - Aldo Angelo Moreira Lima
Universidade Federal do Ceará, Brasil; Universidade Federal do Ceará, Brasil
6 shared publications Richard L. Guerrant
Division of Infectious Diseases and International Health, School of Medicine, University of Virginia, Charlottesville, VA, USA
6 shared publications- Edward J. van Opstal
Biological Sciences, Vanderbilt University, Nashville, TN, United States
5 shared publications
Latest Publications
- Open Access
- 29 August 2026
- Published by Springer Nature in Gut Pathogens
Fecal S100 calcium-binding protein B as a marker for disease severity in patients with Clostridioides difficile infection
- 29 August 2026
- Published by Springer Nature in Gut Pathogens
Open AccessFecal S100 calcium-binding protein B as a marker for disease severity in patients with Clostridioides difficile infection
- Open Access
- 25 August 2026
- Published by Springer Nature in Journal of Neuroinflammation
Clostridioides difficile colitis promotes neuroinflammatory responses in the prefrontal cortex: a preclinical study in mice
- 25 August 2026
- Published by Springer Nature in Journal of Neuroinflammation
Open AccessClostridioides difficile colitis promotes neuroinflammatory responses in the prefrontal cortex: a preclinical study in mice
- Open Access
- 1 July 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (7) , ofag408
Clostridioides difficile Infection–Associated Functional Bowel Disorder: A Three-Year Cohort Study
Background: Recurrent diarrhea after an episode of Clostridioides difficile infection (CDI) is common although not always secondary to recurrent disease. Bacterial and viral gastroenteritis has been associated with postinfectious functional bowel disorders (FBDs). We aimed to compare characteristics of patients diagnosed with CDI-associated FBD with those of patients diagnosed with initial or recurrent CDI alone. Methods: This was a retrospective review of the electronic medical records of patients referred to the Complicated C. difficile Clinic at University of Virginia Health from March 2020 to January 2023. The characteristics of the patients we studied included demographics, risk factors, and outcomes. Results: Of 159 patients seen at the clinic, 44 (27.7%) referred for recurrent CDI had symptoms of FBD; 90 (56.6%) had symptoms of CDI alone. Compared with patients with CDI only, patients with CDI-associated FBD were younger (P = .001), more likely to be female (P = .029), had fewer comorbidities (P < .001), and more frequently had a history of anxiety (P < .001) and depression (P = .003). In a multiple regression model, FBD remained associated with fewer comorbidities (P = .032). At 3 months, patients with FBD were less frequently well (P = .039) and more frequently continued to have gastrointestinal symptoms (P < .001) than patients with CDI alone. Conclusions: CDI-associated FBD is prevalent but may be misdiagnosed as solely CDI recurrence, contributing to incomplete resolution of symptoms despite anti–C. difficile treatments.
- 1 July 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (7) , ofag408
Open AccessClostridioides difficile Infection–Associated Functional Bowel Disorder: A Three-Year Cohort Study
Background: Recurrent diarrhea after an episode of Clostridioides difficile infection (CDI) is common although not always secondary to recurrent disease. Bacterial and viral gastroenteritis has been associated with postinfectious functional bowel disorders (FBDs). We aimed to compare characteristics of patients diagnosed with CDI-associated FBD with those of patients diagnosed with initial or recurrent CDI alone. Methods: This was a retrospective review of the electronic medical records of patients referred to the Complicated C. difficile Clinic at University of Virginia Health from March 2020 to January 2023. The characteristics of the patients we studied included demographics, risk factors, and outcomes. Results: Of 159 patients seen at the clinic, 44 (27.7%) referred for recurrent CDI had symptoms of FBD; 90 (56.6%) had symptoms of CDI alone. Compared with patients with CDI only, patients with CDI-associated FBD were younger (P = .001), more likely to be female (P = .029), had fewer comorbidities (P < .001), and more frequently had a history of anxiety (P < .001) and depression (P = .003). In a multiple regression model, FBD remained associated with fewer comorbidities (P = .032). At 3 months, patients with FBD were less frequently well (P = .039) and more frequently continued to have gastrointestinal symptoms (P < .001) than patients with CDI alone. Conclusions: CDI-associated FBD is prevalent but may be misdiagnosed as solely CDI recurrence, contributing to incomplete resolution of symptoms despite anti–C. difficile treatments.
- Open Access
- 18 June 2026
- Published by Elsevier in Journal of Infection
- Vol. 93 (2) , 106800
Multi-strain Clostridioides difficile infection: Increased detection and clinical implications
- 18 June 2026
- Published by Elsevier in Journal of Infection
- Vol. 93 (2) , 106800
Open AccessMulti-strain Clostridioides difficile infection: Increased detection and clinical implications
- 22 May 2025
- Published by Springer Nature in Nature Reviews Gastroenterology & Hepatology
- Vol. 22 (8) , 570-586
The role of the enteric nervous system in the pathogenesis of Clostridioides difficile infection
Clostridioides difficile is the leading cause of antibiotic-associated diarrhoea worldwide. In the USA, C. difficile infection (CDI) is the eighth leading cause for hospital readmission and seventh for mortality among all gastrointestinal disorders. Gastrointestinal dysmotility and/or diarrhoea occurs after the acute phase of CDI, but persistent gastrointestinal dysfunction post-infection supports contributions of neuroplasticity in the enteric nervous system (ENS), which has a key role in regulating intestinal motility and secretion, in the natural course of CDI. Here, our goal is to provide an up-to-date summary of how the ENS and extrinsic innervation of the gut are affected by CDI and how ENS responses contribute to CDI pathogenesis and outcomes. Enteric neurons and glia are targets of C. difficile toxins in humans and in preclinical model, and changes to the ENS and extrinsic innervation contribute to intestinal inflammation, damage and secretory diarrhoea. These findings suggest possible bidirectional interaction between CDI and the ENS. More studies focusing on understanding how various neurotransmitters and mediators released by the ENS and extrinsic neurons modulate immune responses to CDI could provide insight into novel pharmacological approaches to balance the host response, improve the management of CDI and prevent gastrointestinal dysfunction post-infection.
- 22 May 2025
- Published by Springer Nature in Nature Reviews Gastroenterology & Hepatology
- Vol. 22 (8) , 570-586
The role of the enteric nervous system in the pathogenesis of Clostridioides difficile infection
Clostridioides difficile is the leading cause of antibiotic-associated diarrhoea worldwide. In the USA, C. difficile infection (CDI) is the eighth leading cause for hospital readmission and seventh for mortality among all gastrointestinal disorders. Gastrointestinal dysmotility and/or diarrhoea occurs after the acute phase of CDI, but persistent gastrointestinal dysfunction post-infection supports contributions of neuroplasticity in the enteric nervous system (ENS), which has a key role in regulating intestinal motility and secretion, in the natural course of CDI. Here, our goal is to provide an up-to-date summary of how the ENS and extrinsic innervation of the gut are affected by CDI and how ENS responses contribute to CDI pathogenesis and outcomes. Enteric neurons and glia are targets of C. difficile toxins in humans and in preclinical model, and changes to the ENS and extrinsic innervation contribute to intestinal inflammation, damage and secretory diarrhoea. These findings suggest possible bidirectional interaction between CDI and the ENS. More studies focusing on understanding how various neurotransmitters and mediators released by the ENS and extrinsic neurons modulate immune responses to CDI could provide insight into novel pharmacological approaches to balance the host response, improve the management of CDI and prevent gastrointestinal dysfunction post-infection.
- 10 May 2025
- Published by Springer Nature
- p. 1-24
ApoE and Intestinal Mucosal Immunity
- 11 April 2025
- Published by Elsevier in The Journal of Nutrition
- Vol. 155 (6) , 1700-1709
Clostridioides difficile Infection in Aged Mice Decreases Memory Function, Which Can Be Protected with Alanyl-Glutamine Supplementation
- 11 April 2025
- Published by Elsevier in The Journal of Nutrition
- Vol. 155 (6) , 1700-1709
Clostridioides difficile Infection in Aged Mice Decreases Memory Function, Which Can Be Protected with Alanyl-Glutamine Supplementation
- 21 February 2025
- Published by Elsevier in Medical Clinics of North America
- Vol. 109 (3) , 721-734
Fulminant Clostridioides difficile Infection
- 21 February 2025
- Published by Elsevier in Medical Clinics of North America
- Vol. 109 (3) , 721-734
Fulminant Clostridioides difficile Infection
- Open Access
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
2249. Piperacillin-tazobactam-targeted provider education to improve utilization in a small community hospital
Piperacillin-tazobactam is a broad-spectrum antibiotic commonly used for the treatment of Pseudomonas aeruginosa and other susceptible Gram negative and anaerobic infections. Piperacillin-tazobactam utilization is markedly elevated in our institution compared with regional and national rates.Thus, interventions to promote optimal use of this antibiotic to reduce utilization rates and negative consequences are needed. Healthcare providers were provided with guidelines on piperacillin-tazobactam alternative treatments for various infections. Guideline handouts were disseminated and complemented by in-person presentations and one-on-one case discussions, as needed. Data on piperacillin-tazobactam utilization was gathered using BD Medmined’s medication analytics. Total antibiotic utilization at our institution is higher compared to national and regional rates. In the 2nd quarter (Q2) of 2021, piperacillin-tazobactam utilization was 44% and 26% above national and regional comparative rates, respectively. In Q2 2022, piperacillin-tazobactam was 59% and 45% higher, respectively. Immediately post-initiation of intervention (Q3 2022), utilization rates dropped to 34% and 22%, respectively and utilization dropped further in the succeeding quarters attaining comparable rates to national and regional comparator hospitals. Providing healthcare providers with antibiotic-targeted education on alternative treatments can significantly reduce the utilization of piperacillin-tazobactam. Further studies are warranted to evaluate the long-term impact of this intervention on antibiotic stewardship in small community hospitals. Cirle A. Warren, MD, Ser-109 Coactuate: Advisor/Consultant|Ser-109 Coactuate: Honoraria
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
Open Access2249. Piperacillin-tazobactam-targeted provider education to improve utilization in a small community hospital
Piperacillin-tazobactam is a broad-spectrum antibiotic commonly used for the treatment of Pseudomonas aeruginosa and other susceptible Gram negative and anaerobic infections. Piperacillin-tazobactam utilization is markedly elevated in our institution compared with regional and national rates.Thus, interventions to promote optimal use of this antibiotic to reduce utilization rates and negative consequences are needed. Healthcare providers were provided with guidelines on piperacillin-tazobactam alternative treatments for various infections. Guideline handouts were disseminated and complemented by in-person presentations and one-on-one case discussions, as needed. Data on piperacillin-tazobactam utilization was gathered using BD Medmined’s medication analytics. Total antibiotic utilization at our institution is higher compared to national and regional rates. In the 2nd quarter (Q2) of 2021, piperacillin-tazobactam utilization was 44% and 26% above national and regional comparative rates, respectively. In Q2 2022, piperacillin-tazobactam was 59% and 45% higher, respectively. Immediately post-initiation of intervention (Q3 2022), utilization rates dropped to 34% and 22%, respectively and utilization dropped further in the succeeding quarters attaining comparable rates to national and regional comparator hospitals. Providing healthcare providers with antibiotic-targeted education on alternative treatments can significantly reduce the utilization of piperacillin-tazobactam. Further studies are warranted to evaluate the long-term impact of this intervention on antibiotic stewardship in small community hospitals. Cirle A. Warren, MD, Ser-109 Coactuate: Advisor/Consultant|Ser-109 Coactuate: Honoraria